Real World Patient Perceptions of the use of Calcipotriene Foam 0.005% in the Treatment of Plaque Psoriasis
Gupta R, Debbaneh MG, Liao W, Genetic Epidemiology of Psoriasis. Curr Dermatol Rep. 2014 March; 3(1):61-78.
Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is
associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9.
Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv. 2012 Oct;9(10):1263-71.
Stein Gold LF. Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence. Semin Cutan Med Surg. 2016 Mar;35(2 Suppl 2):S36 44; quiz S45.
Del Rosso JQ, Kircik LH, Zeichner J, Stein Gold L. The Clinical
Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles: Vehicle Characteristics Can Influence and Improve Patient Outcomes. J Drugs Dermatol. 2019 Feb 1;18(2s):s100-s107.
Eastman WJ, Malahias S, Delconte J, DiBenedetti D. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis. 2014 July;94(1):46-53.
Feldman, SR, Mills, M, Brundage, T, & Eastman, WJ (2013, March). A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp. JDD, 12(3), 300-306.
Data on File, Mayne Pharma, Inc.
Abstract - 85 Poster PDF - 17
- There are currently no refbacks.